Search

Displaying results 351 - 360 of 4265 in total
  1. Drug

    Pivmecillinam

    go.drugbank.com/drugs/DB01605
    ApprovedInvestigational

    Pivmecillinam is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa.

  2. Drug

    Bepotastine

    go.drugbank.com/drugs/DB04890
    Approved

    Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the

  3. Drug

    BacTRL-spike

    go.drugbank.com/drugs/DB15811
    Investigational

    BacTRL-Spike is composed of a bacterial medium with colony-forming-units of live Bifidobacterium longum engineered to deliver synthetic DNA encoding spike protein from SARS-CoV-2 contained by plasmids. … The vaccine was developed by Symvivo Corporation.

  4. Drug

    Moxisylyte

    go.drugbank.com/drugs/DB09205
    Approved

    [L1172] This drug was developed by the Japanese company Fujirebio and also by the American company Iolab in the late 80s. … [T45] According to the WHO, moxisylyte is approved since 1987[T91] and in the same year, it acquired the denomination of orphan product by the FDA.

  5. Drug

    Human botulinum neurotoxin A/B immune globulin

    go.drugbank.com/drugs/DB14115
    Approved

    [L39819,L39824] BabyBIG (human-derived botulism immunoglobulin) was approved for use by the FDA in 2003[L39814] and has since been used to treat more than 2100 cases of infant botulism. … [L39834] It is produced and distributed by the Calfornia Department of Public Health's Infant Botulism Treatment and Prevention Program[L39829] and comprises IgG antibodies derived from pooled adult plasma

  6. Drug

    Grepafloxacin

    go.drugbank.com/drugs/DB00365
    ApprovedWithdrawn

    Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States

  7. Drug

    Fludeoxyglucose (18F)

    go.drugbank.com/drugs/DB09502
    ApprovedInvestigational

    It is administered by intravenous injection.

  8. Drug

    Cefoxitin

    go.drugbank.com/drugs/DB01331
    ApprovedInvestigational

    It is derived from cephamycin C, which is produced by <i>Streptomyces lactamdurans</i>.

  9. Drug

    Cromoglicic acid

    go.drugbank.com/drugs/DB01003
    ApprovedInvestigational

    It is used in the prophylactic treatment of both allergic and exercise-induced asthma, but does not affect an established asthmatic attack. … A chromone complex that acts by inhibiting the release of chemical mediators from sensitized mast cells.

  10. Drug

    Daridorexant

    go.drugbank.com/drugs/DB15031
    ApprovedInvestigational

    [A244280] Daridorexant was approved by the European Commission on May 3, 2022, as the first dual orexin receptor antagonist approved in the market,[L41725] and by Health Canada on April 26, 2023. … Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of daytime functioning.